Targeting Enteropeptidase with Reversible Covalent Inhibitors To Achieve Metabolic Benefits
作者:Weimei Sun、Xuqing Zhang、Maxwell D. Cummings、Kamal Albarazanji、Jiejun Wu、Mina Wang、Richard Alexander、Bin Zhu、YueMei Zhang、James Leonard、James Lanter、James Lenhard
DOI:10.1124/jpet.120.000219
日期:2020.12
of camostat, leading to formation of the carboxyphenylguanidine acyl enzyme identical to that expected for the reaction with camostat. Of particular note, minor structural modifications of camostat led to changes in the mechanism of inhibition. We observed from other studies that sustained inhibition of EP is required to effect a reduction in cumulative food intake and body weight, with concomitant improved
丝氨酸蛋白酶肠肽酶(EP)的抑制为发现用于治疗代谢性疾病的化学疗法开辟了一条新途径。在日本,卡莫司他已被临床用于治疗慢性胰腺炎。但是,尚未完全阐明观察到的临床疗效的机理基础。我们证明了camostat是EP的有效可逆共价抑制剂,其抑制力(k inact / K I)为1.5×10 4 M -1 s -1。高分辨率液相色谱-质谱(LC-MS)显示,在与卡莫司他反应后,EP中添加了161.6 Da,这与卡莫司他的羧基苯基胍部分的插入相符。camostat对EP的共价抑制是可逆的,酶的半衰期为14.3小时。共价加合物的形成进一步受到解析为2.19Å的晶体结构的支持,这表明密莫司他的紧密类似物对EP的催化丝氨酸进行了修饰,导致形成了羧基苯胍基酰基转移酶,与预期的相同。特别要注意的是,稳压器的微小结构修饰导致了抑制机制的改变。我们从其他研究中观察到,需要持续抑制EP才能减少累积食物摄入量和体重,同时